Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Ticagrelor is a direct acting on the P2Y12 receptor blocker, which provides faster and greater platelet inhibition than clopidogrel. However, several studies suggested that in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention (PCI), ticagrelor exhibits...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Medicine (Baltimore)
Main Authors: Liu, Hui-Liang, Wei, Yu-Jie, Jin, Zhi-Geng, Zhang, Jiao, Ding, Peng, Yang, Sheng-Li, Luo, Jian-Ping, Ma, Dong-Xing, Liu, Ying, Han, Wei
פורמט: Artigo
שפה:Inglês
יצא לאור: Wolters Kluwer Health 2016
נושאים:
3400
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4900712/
https://ncbi.nlm.nih.gov/pubmed/27258504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003756
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים